Hing Sham - Global Blood Senior Vice President - Chemistry
GBTDelisted Stock | USD 68.49 0.00 0.00% |
President
Dr. Hing Sham, Ph.D. is Senior Vice President, Research of the company. He was Senior Vice President, Chemistry, from July 2014 to April 2016. Most recently, from January 2013 to July 2014, Dr. Sham served as head of research and development at iOneWorldHealthPath.org, a nonprofit pharmaceutical development organization. Prior to that, from September 2006 to November 2012, he served as senior vice president of research and head of chemical sciences at Elan Pharmaceuticals, Inc., a biopharmaceutical company, where he led the chemistry team in the discovery of two clinical candidates for the treatment of Alzheimers disease. From July 1983 to August 2006, Dr. Sham worked at Abbott Laboratories Inc., a global healthcare company, where he and his team discovered and advanced 10 clinical candidates spanning cardiovascular disease, HIV, oncology and diabetes. His 24year tenure at Abbott Laboratories culminated in his appointment as a distinguished research fellow in global pharmaceutical discovery. Dr. Sham is the coinventor of Norvir and the primary inventor of Kaletra, Abbott Laboratories first and secondgeneration HIV protease inhibitors approved for the treatment of HIV. Dr. Sham has published more than 180 scientific articles in peerreviewed journals and is a named inventor on 81 issued U.S. patents. Dr. Sham was named Hero of Chemistry by the American Chemical Society in 2003 since 2016.
Age | 64 |
Tenure | 8 years |
Professional Marks | Ph.D |
Phone | 650 741-7700 |
Web | www.globalbloodtx.com |
Global Blood Management Efficiency
The company has Return on Asset of (23.82) % which means that on every $100 spent on assets, it lost $23.82. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (124.53) %, meaning that it generated no profit with money invested by stockholders. Global Blood's management efficiency ratios could be used to measure how well Global Blood manages its routine affairs as well as how well it operates its assets and liabilities.The company has 659.05 M in debt with debt to equity (D/E) ratio of 4.92, demonstrating that the company may be unable to create cash to meet all of its financial commitments. Global Blood Therapeutics has a current ratio of 8.35, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Debt can assist Global Blood until it has trouble settling it off, either with new capital or with free cash flow. So, Global Blood's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Global Blood Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Global to invest in growth at high rates of return. When we think about Global Blood's use of debt, we should always consider it together with cash and equity.
Similar Executives
Showing other executives | PRESIDENT Age | ||
Ferdinand Jahnel | Marsh McLennan Companies | N/A | |
John Micenko | United Homes Group | N/A | |
Alison Rand | Primerica | 56 | |
William Kelly | Primerica | 65 | |
Tsai Pan | Tencent Music Entertainment | 50 | |
Andrew Levine | SL Green Realty | 65 | |
Michael Adams | Primerica | 67 | |
Robert Peterman | Primerica | 58 | |
Kevin Brown | MI Homes | N/A | |
Stacy Mills | Marsh McLennan Companies | 59 | |
Kathryn Kieser | Primerica | 51 | |
Peter Beshar | Marsh McLennan Companies | 58 | |
Peter Schneider | Primerica | 68 | |
Robert Rapport | Marsh McLennan Companies | N/A | |
Jeffrey Fendler | Primerica | 67 | |
Parimala Rao | SL Green Realty | N/A | |
Andrew Mathias | SL Green Realty | 50 | |
Norman Schmeichel | ICC Holdings | 55 | |
E Gilbert | Marsh McLennan Companies | 63 | |
Gregory Pitts | Primerica | 61 | |
Michael Miller | Primerica | 43 |
Management Performance
Return On Equity | -124.53 | |||
Return On Asset | -23.82 |
Global Blood Therapeutics Leadership Team
Elected by the shareholders, the Global Blood's board of directors comprises two types of representatives: Global Blood inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Global. The board's role is to monitor Global Blood's management team and ensure that shareholders' interests are well served. Global Blood's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Global Blood's outside directors are responsible for providing unbiased perspectives on the board's policies.
Lesley Calhoun, Principal Accounting Officer, Vice President - Finance | ||
Michael Bonney, Director | ||
Stephanie Yao, IR Contact Officer | ||
Myesha Lacy, IR Contact Officer | ||
Mark Perry, Independent Director | ||
Jeffrey Farrow, CFO | ||
Myesha Edwards, IR Contact Officer | ||
Philip Pizzo, Director | ||
Glenn Pierce, Director | ||
Willie Brown, Independent Director | ||
Wendy Yarno, Director | ||
Kevin Starr, Director | ||
Hing Sham, Senior Vice President - Chemistry | ||
Scott Morrison, Director | ||
Deval Patrick, Independent Director | ||
Tricia Suvari, Chief Legal Officer | ||
Peter Radovich, Vice President - Program Leadership and Business Strategy | ||
David Johnson, Chief Commercial Officer | ||
Charles Homcy, Director | ||
Dawn Svoronos, Director | ||
Ted Love, President CEO, Director | ||
Eleanor Ramos, Chief Medical Officer | ||
John Schembri, Vice President of Finance and Administration | ||
Jung Choi, Chief Business and Strategy Officer |
Global Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Global Blood a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -124.53 | |||
Return On Asset | -23.82 | |||
Profit Margin | (146.82) % | |||
Operating Margin | (137.33) % | |||
Current Valuation | 2.24 B | |||
Shares Outstanding | 64.45 M | |||
Shares Owned By Insiders | 2.72 % | |||
Shares Owned By Institutions | 97.28 % | |||
Number Of Shares Shorted | 9.23 M | |||
Price To Earning | (13.97) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Global Blood Therapeutics information on this page should be used as a complementary analysis to other Global Blood's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Other Consideration for investing in Global Stock
If you are still planning to invest in Global Blood Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Global Blood's history and understand the potential risks before investing.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities |